Immunosuppressants - BRICS

BRICS

The Immunosuppressants market in BRICS countries is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$5.48bn in 2024.
With an annual growth rate (CAGR 2024-2029) of 15.74%, the market volume is expected to expand to US$11.38bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Immunosuppressants market, with a projected value of US$35,470.00m in 2024.
Brazil, as a leading market in the BRICS, is witnessing a rising demand for immunosuppressants due to the increasing prevalence of autoimmune diseases.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants has been increasing in the BRICS countries due to the rise in chronic diseases, organ transplantations, and autoimmune disorders.

Customer preferences: Patients in BRICS countries prefer immunosuppressants that have fewer side-effects, are cost-effective, and have a high success rate. The demand for generic immunosuppressants has been increasing due to their affordability compared to branded drugs.

Trends in the market: In Brazil, the immunosuppressants market has been growing due to the increasing number of kidney and liver transplantations. The government's initiatives to provide free immunosuppressants to patients have also contributed to the market's growth.In Russia, the market has been growing due to the increasing prevalence of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis. The government's initiatives to promote organ transplantations have also contributed to the market's growth.In India, the market has been growing due to the rise in the number of organ transplantations and the increasing prevalence of autoimmune disorders. The demand for generic immunosuppressants has been increasing due to their affordability.In China, the market has been growing due to the increasing prevalence of chronic diseases such as diabetes and hypertension. The government's initiatives to promote organ transplantations have also contributed to the market's growth.

Local special circumstances: In Brazil, the government's initiatives to provide free immunosuppressants to patients have led to a high demand for these drugs. However, the lack of funding has resulted in a shortage of drugs in some regions.In Russia, the high cost of branded immunosuppressants has led to a high demand for generic drugs. However, the quality of these drugs is often questionable, leading to concerns about their safety and efficacy.In India, the lack of awareness about organ donation has resulted in a shortage of organs for transplantations. This has led to a high demand for immunosuppressants to prevent organ rejection.In China, the lack of regulatory oversight has led to concerns about the safety and efficacy of some immunosuppressants. The government's initiatives to promote organ transplantations have also led to concerns about the ethical implications of these procedures.

Underlying macroeconomic factors: The BRICS countries have been experiencing economic growth, which has led to an increase in healthcare spending. The rise in chronic diseases, organ transplantations, and autoimmune disorders has also contributed to the growth of the immunosuppressants market. However, the lack of regulatory oversight and the high cost of branded drugs have led to concerns about the safety and affordability of these drugs. The demand for generic drugs has been increasing due to their affordability, but the quality of these drugs is often questionable. The government's initiatives to provide free immunosuppressants to patients and promote organ transplantations have also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.